CytoDyn to present updated Phase 2 CLOVER trial data for leronlimab combo in metastatic colorectal cancer at ESMO 2026
Bitget2026/10/08 12:33CytoDyn flagged updated clinical data from its Phase 2 CLOVER trial in metastatic colorectal cancer for presentation at ESMO Congress 2026. Results have not yet been presented; the update is scheduled for Oct. 25, 2026, in Madrid. The study evaluates leronlimab alongside established therapies in previously treated patients, aiming to improve outcomes in hard-to-treat disease. Management framed the update as supporting its strategy to advance leronlimab in combination regimens across solid tumors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080830PRIMZONEFULLFEED9841888) on October 08, 2026, and is solely responsible for the information contained therein.
- CytoDyn flagged updated clinical data from its Phase 2 CLOVER trial in metastatic colorectal cancer for presentation at ESMO Congress 2026.
- Results have not yet been presented; the update is scheduled for Oct. 25, 2026, in Madrid.
- The study evaluates leronlimab alongside established therapies in previously treated patients, aiming to improve outcomes in hard-to-treat disease.
- Management framed the update as supporting its strategy to advance leronlimab in combination regimens across solid tumors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
